Constipation, IBs and the 5-HT 4 Receptor: What Role for Prucalopride?
Clinical Medicine. Gastroenterology · 2010
DOI: 10.4137/cgast.s4136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Gastroenterology, 2010. Verfasst von Gareth J. Sanger und 1 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 98 Literaturangaben.
Abstract (Originalsprache)
After the problems associated with the non-selective 5-HT 4 receptor agonists cisapride and tegaserod, the 5-HT 4 receptor is now beginning to come in from the cold. Thus, prucalopride is now the first of a new class of drug defined by selectivity and high intrinsic activity at the 5-HT 4 receptor. Prucalopride has been developed for treatment of chronic constipation rather than constipation-predominant irritable bowel syndrome (IBS). This follows the trend of first evaluating new gastrointestinal (GI) prokinetic drugs in disorders where disrupted GI motility is known to exist, rather than in a functional bowel disorder where changes in motility are uncertain. If prucalopride is not progressed towards the IBS indication, it has at least shown the way for other selective 5-HT 4 receptor agonists. Most notable among these is TD-5108 (velusetrag), also characterized by good selectivity at the 5-HT 4 receptor, high intrinsic activity and efficacy in patients with chronic constipation.
Zitieren
APA
Sanger, G. J., & Quigley, E. M. (2010). Constipation, IBs and the 5-HT 4 Receptor: What Role for Prucalopride?. Clinical Medicine. Gastroenterology. https://doi.org/10.4137/cgast.s4136
Vancouver
Sanger GJ, Quigley EM. Constipation, IBs and the 5-HT 4 Receptor: What Role for Prucalopride?. Clinical Medicine. Gastroenterology. 2010. doi:10.4137/cgast.s4136
BibTeX
@article{Sanger2010,
author = {Sanger, Gareth J. and Quigley, Eamonn M.M.},
title = {Constipation, IBs and the 5-HT 4 Receptor: What Role for Prucalopride?},
journal = {Clinical Medicine. Gastroenterology},
year = {2010},
doi = {10.4137/cgast.s4136}
}
EUVIMED